Description
Jointly provided by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc.
Original Release Date: May 2018
Release Date: February 2024
Expiration Date: February 2025
Speaker: Dr. Richard Lewis
Speaker: Dr. Mazen Dimachkie
Speaker: Jeffrey Rosenfeld , MD, PhD
Continuing Education: Nursing 2 contact hour | Pharmacy 2 contact hour
Recertification: 2 IgCN® / IgCP® Recertification Units
Target Audience
This activity is intended for pharmacists and nurses who care for patients with CIDP.
Educational Objectives
Upon completion of this activity, participants should be able to:
Session 1:
- Describe the diagnostic triad used for evaluating patients
- Describe the role of auto-antibodies in CIDP
- Describe the four variants of CIDP
Session 2:
- List three factors of consideration in determining to initiate therapy
- Describe three treatment options for CIDP
- Discuss the risks and benefits of CIDP treatment modalities
Session 3:
- Describe two characteristics of CIDP
- Discuss three techniques to evaluate clinical response to Ig therapy
- Compare and contrast IVIG vc SCIG in managing CIDP
